News articles about Emergent Biosolutions (NYSE:EBS) have been trending somewhat positive on Saturday, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Emergent Biosolutions earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 47.1025846980532 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern Sentiment’s analysis:

Emergent Biosolutions (EBS) traded up 1.08% on Friday, hitting $34.51. The stock had a trading volume of 222,401 shares. The company has a 50 day moving average of $34.85 and a 200 day moving average of $31.50. The company has a market capitalization of $1.42 billion, a PE ratio of 21.98 and a beta of 1.22. Emergent Biosolutions has a 12-month low of $24.47 and a 12-month high of $36.95.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by $0.13. The company had revenue of $100.77 million for the quarter, compared to analysts’ expectations of $111.57 million. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) EPS. On average, equities analysts expect that Emergent Biosolutions will post $1.55 earnings per share for the current year.

A number of research analysts have commented on EBS shares. BidaskClub lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Zacks Investment Research lowered Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Emergent Biosolutions presently has a consensus rating of “Hold” and a consensus target price of $44.00.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at

In related news, Chairman Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $35.50, for a total value of $887,500.00. Following the transaction, the chairman now owns 1,655,216 shares in the company, valued at approximately $58,760,168. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 16.50% of the stock is owned by company insiders.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with's FREE daily email newsletter.